Identification of human monoclonal antibodies specific for human SOD1 recognizing distinct epitopes and forms of SOD1 by Broering, Teresa J. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
University of Massachusetts Medical School Faculty Publications 
2013-04-17 
Identification of human monoclonal antibodies specific for human 
SOD1 recognizing distinct epitopes and forms of SOD1 
Teresa J. Broering 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/faculty_pubs 
 Part of the Biochemistry Commons, Immunoprophylaxis and Therapy Commons, Nervous System 
Diseases Commons, and the Neurology Commons 
Repository Citation 
Broering TJ, Wang H, Boatright NK, Wang Y, Baptista K, Shayan G, Garrity KA, Kayatekin C, Bosco DA, 
Matthews CR, Ambrosino DM, Xu Z, Babcock GJ. (2013). Identification of human monoclonal antibodies 
specific for human SOD1 recognizing distinct epitopes and forms of SOD1. University of Massachusetts 
Medical School Faculty Publications. https://doi.org/10.1371/journal.pone.0061210. Retrieved from 
https://escholarship.umassmed.edu/faculty_pubs/90 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in University of 
Massachusetts Medical School Faculty Publications by an authorized administrator of eScholarship@UMMS. For 
more information, please contact Lisa.Palmer@umassmed.edu. 
Identification of Human Monoclonal Antibodies Specific
for Human SOD1 Recognizing Distinct Epitopes and
Forms of SOD1
Teresa J. Broering1*¤a, Hongyan Wang2, Naomi K. Boatright1, Yang Wang1, Katherine Baptista1,
Gilda Shayan1¤b, Kerry A. Garrity1¤c, Can Kayatekin2¤d, Daryl A. Bosco2,3, C. Robert Matthews2,
Donna M. Ambrosino1¤e, Zuoshang Xu2,4,5, Gregory J. Babcock1¤e
1MassBiologics, University of Massachusetts Medical School, Boston, Massachusetts, United States of America, 2Department of Biochemistry and Molecular
Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America, 3Department of Neurology, University of Massachusetts
Medical School, Worcester, Massachusetts, United States of America, 4Department of Cell Biology, University of Massachusetts Medical School, Worcester, Massachusetts,
United States of America, 5Neuroscience Program, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
Abstract
Mutations in the gene encoding human SOD1 (hSOD1) can cause amyotrophic lateral sclerosis (ALS) yet the mechanism by
which mutant SOD1 can induce ALS is not fully understood. There is currently no cure for ALS or treatment that significantly
reduces symptoms or progression. To develop tools to understand the protein conformations present in mutant SOD1-
induced ALS and as possible immunotherapy, we isolated and characterized eleven unique human monoclonal antibodies
specific for hSOD1. Among these, five recognized distinct linear epitopes on hSOD1 that were not available in the properly-
folded protein but were available on forms of protein with some degree of misfolding. The other six antibodies recognized
conformation-dependent epitopes that were present in the properly-folded protein with two different recognition profiles:
three could bind hSOD1 dimer or monomer and the other three were specific for hSOD1 dimer only. Antibodies with the
capacity to bind hSOD1 monomer were able to prevent increased hydrophobicity when mutant hSOD1 was exposed to
increased temperature and EDTA, suggesting that the antibodies stabilized the native structure of hSOD1. Two antibodies
were tested in a G93A mutant hSOD1 transgenic mouse model of ALS but did not yield a statistically significant increase in
overall survival. It may be that the two antibodies selected for testing in the mouse model were not effective for therapy or
that the model and/or route of administration were not optimal to produce a therapeutic effect. Therefore, additional
testing will be required to determine therapeutic potential for SOD1 mutant ALS and potentially some subset of sporadic
ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s
disease, is characterized by progressive motor neuron degenera-
tion, muscle wasting and paralysis [1]. There is currently no cure
and paralysis progressively proceeds from loss of gross motor
control to loss of breathing capacity and ultimately death. Motor
neurons are selectively affected with cognitive function largely
retained. Current treatments consist primarily of supportive care
and one approved drug Riluzole, which provides a modest
extension of life of approximately three months [2].
Of patients diagnosed with ALS, approximately 10% have a
family history of the disease (familial ALS or fALS), and the other
90% have no known family history (sporadic ALS or sALS).
Mutations in multiple genes have been associated with fALS, and
the gene encoding Cu/Zn superoxide dismutase 1 (SOD1) has
mutations in approximately 20% of fALS cases, ranking second in
frequency among currently identified gene mutations [3–5].
Symptoms of sALS and fALS are clinically indistinguishable
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suggesting that there may be common pathways involved in both
forms of the disease [6]. Recent work suggests that oxidized or
misfolded SOD1 can be found in some but not all sALS patients
[7–10]. Thus, misfolded SOD1 could be involved in disease
pathogenesis in both fALS and sALS patients.
SOD1 is ubiquitously expressed in the cytoplasm with high
levels in motor neurons. The 32 kDa SOD1 homodimer contains
two molecules of both copper and zinc with an intramolecular
disulfide bond present in each monomer [11]. There are over 150
different identified mutations in the 153 amino acid human SOD1
protein (hSOD1) that are associated with fALS (http://alsod.iop.
kcl.ac.uk/als). Mutant hSOD1 protein expression has many
documented effects on cells: disruption of axonal transport [7],
interference with mitochondrial function [12], inclusion formation
[13], atypical secretion of hSOD1 from cells [14], and others.
However, the mechanisms of disease pathology and symptoms
caused by mutant hSOD1 are not fully understood [15]. A
common effect of various mutations in hSOD1 is decreased SOD1
stability and an increased propensity of SOD1 to misfold and
aggregate [16]. It is proposed that misfolded SOD1 may directly
or indirectly cause motor neuron death.
Several well-established transgenic mouse models expressing
different mutant hSOD1 proteins display the hallmarks of ALS
[17–19]. Mice expressing mutant hSOD1 develop progressive
paralysis that proceeds to an early death with evidence of motor
neuron loss. This type of rodent model has been used to test
numerous different compounds, but translation of treatments from
the mouse model to human therapeutics has proven difficult [20].
To date, none of the many compounds tested have provided
benefit to the human population with the exception of Riluzole
which showed effects in rodent models of disease that were very
modest and similar to many other compounds [21], [22]. The lack
of correlation may be due to a multitude of factors including
variation in the animal models and mutations in hSOD1
representing a small percentage of the total human ALS
population.
Previous data from immunization and passive antibody transfer
to mutant hSOD1 transgenic mice has provided an extension in
survival in some mouse models. Immunization of G37R hSOD1
transgenic mice with mutant hSOD1 or immunization of low-copy
G93A transgenic mice with mutant or wild-type hSOD1 lacking
copper and zinc (apo-hSOD1) led to a delay in disease endpoint of
30 days and 14 days respectively [23], [24]. Similar immunizations
in high-copy G93A transgenic mice did not result in a statistically
significant delay of disease endpoint [23], [24]. hSOD1 dimer
interface (SEDI) peptide immunization of G37R hSOD1 trans-
genic mice delayed disease endpoint 40 days [25]. The same
peptide immunization in the high-copy G93A transgenic mouse
model delayed disease endpoint 7 days but was not statistically
significant [25]. Passive transfer of a proportion of mouse
antibodies specific for hSOD1 also gave a small (6 days) but
statistically significant delay in disease endpoint in the high-copy
G93A hSOD1 mouse model [23], [26]. These results suggest that
antibodies specific to mutant or misfolded hSOD1 may be an
effective therapeutic for fALS with SOD1 mutation and poten-
tially some cases of sALS.
To further pursue potential immunotherapy for fALS with
SOD1 mutation, we generated a panel of fully human monoclonal
antibodies (HuMabs) directed against hSOD1 to allow direct
translation to treatment in affected individuals. The isolated
HuMabs recognized various epitopes of hSOD1, and some
HuMabs specifically recognized unfolded or misfolded but not
properly-folded hSOD1. A select number of HuMabs were tested
in a hSOD1 mutant transgenic mouse model. This panel of
HuMabs should prove useful to probe the structure of various
forms of hSOD1 in ALS and may have potential as a therapeutic.
Materials and Methods
Cells and Cell Culture
HEK-293T/17 and P3X-AG8.653 cells were obtained from the
American Type Culture Collection (ATCC). HEK-293T/17 cells
were grown in Dulbecco’s modified Eagle’s media (DMEM)
supplemented with 10% fetal bovine serum (FBS) and 100 IU
penicillin-streptomycin. P3X-AG8.653 cells were grown in a
supplemented RPMI media and hybridomas were cultured in a
DMEM supplemented media as previously described [27]. All cells
were grown at 37uC in air supplemented with 5% CO2.
Expression and Purification of Human SOD1 Fusion
Proteins from Bacteria
A bacterially codon-optimized gene encoding the wild-type
(WT) hSOD1 protein (UniProtKB/Swiss-Prot accession number
P00441) was synthesized by Integrated DNA Technologies (IDT)
and the sequence was confirmed. To express this protein in
bacteria with an amino-terminal (N-terminal) thioredoxin fusion
and carboxy-terminal (C-terminal) 6-histidine tag, the gene was
subcloned from the vector provided from IDT into pET32a(+)
(EMD) in frame with the upstream thioredoxin (Trx) gene and
downstream 6-histidine tag using BamHI and SalI. The Trx N-
terminal fusion led to increased solubility and higher expression
levels allowing large amounts of protein production for use in the
initial screening assays. To express hSOD1 in bacteria with an N-
terminal glutathione sulfur transferase (GST) fusion, the gene was
subcloned from the vector provided from IDT into pGEX-4T-3
(GE Healthcare) in frame with the upstream GST gene employing
BamHI and SalI. BL21Star Escherichia coli cells (Invitrogen) were
transformed with pET32a(+) and pGEX-4T-3 vectors and grown
overnight at 37uC in Luria-Bertani broth containing 100 mg/ml
ampicillin (LB-amp). The culture was diluted 1:10 in LB-amp
broth and grown for 2.5 hours at 37uC followed by addition of
1 mM isopropyl-ß-d-thiogalactopyranoside and further grown at
37uC for 2.5 hours. Bacteria were harvested by centrifugation and
pellets were frozen at -20uC. Bacteria were lysed and proteins
purified as described previously [28] employing Ni-NTA agarose
for pET32a(+) vectors and glutathione sepharose for pGEX-4T-3
vectors. The human SOD1 expressed from bacteria with a Trx
and 6-histidine tag is referred to as Trx-hSOD1-WT-his and the
glutathione fusion is referred to as GST-hSOD1-WT. Mutagenesis
of the bacterially codon optimized hSOD1 in the pET32a(+)
expression plasmid was performed using the Quick Change II Site-
Directed Mutagenesis kit (Stratagene) following the manufacturer’s
instructions to introduce the following mutations into the hSOD1
gene: A4V, G93A, and G85R. DNA encoding fragments of SOD1
were amplified from pET-32a-hSOD1 using various sequence
specific oligonucleotide primers and cloned into pET32a(+) in
frame with the C-terminal 6-histidine tag. All constructs were
confirmed by DNA sequencing. The hSOD1 mutants and
fragments were expressed and purified as described above for
the full-length Trx-hSOD1-WT-his protein.
Mouse Immunizations and Hybridoma Isolation
Transgenic mice comprising unrearranged human immuno-
globulin genes and inactivated mouse heavy and kappa-light chain
loci [29] (provided by Medarex, Inc., a wholly owned subsidiary of
Bristol-Myers Squibb Company) were injected weekly for a total of
7–20 weeks with 100 mg of various hSOD1 proteins mixed with
Sigma adjuvant system (Sigma). This study was performed in
Human Monoclonal Antibodies to Human SOD1
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accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health. The protocol was approved by the Institutional Animal
Care and Use Committee at the University of Massachusetts
Medical School (protocol A-1780). Mammalian hSOD1 protein
purified from human erythrocytes was purchased from Sigma (E-
hSOD1) and has been previously noted to have post-translational
modifications [30]. ELISA was employed to measure serum
responses to antigen and animals were sacrificed when serum
responses reached a plateau. Hybridomas were generated by the
standard polyethylene glycol (PEG) method using P3X63-
AG8.653 mouse myeloma cells as fusion partner.
ELISA
Culture supernatants or purified antibody were assessed for
antigen binding using ELISA. Microtiter plates (96 well) were
coated with 100 ml per well of 0.5–2 mg/ml of antigen in
phosphate buffered saline, pH 7.4 (PBS) overnight at 4uC.
Antibody (100 ml) at varying dilutions was added and incubated
at room temperature for 1 hr. Antibody binding was detected
using an anti-human IgG-alkaline phosphatase (AP) conjugate
(1:5000, Jackson Immunoresearch) followed by p-nitrophenyl
phosphate disodium salt (PNPP) at 1 mg/ml in 1 M diethanol-
amine. Absorbance (405 nm) was analyzed using Molecular
Devices Emax plate reader with the Softmax software. For peptide
specific ELISAs, overlapping peptides (New England Peptide)
containing N-terminal long chain biotin were bound to strepta-
vidin coated plates (Nunc) by incubating 100 ml per well of 1 mg/
ml of peptide in PBS +0.05% Tween-20 at room temperature for
1 hr. The plates were then washed and antibody binding to
peptides was detected using identical reagents as described above.
Antibody Cloning, Expression, and Purification
Heavy and light chain variable regions were amplified from
hybridoma RNA as described previously [27]. Heavy chain
variable region PCR products were cloned into a mammalian
expression vector in frame with human IgG1 constant region
contained in the vector. Amplified light chain variable regions
were cloned into a mammalian expression vector in frame with the
human kappa constant region present in the vector. Heavy and
light chain vectors were combined to a single vector and
electroporated into CHO cells. Stable transfectants were selected
and expanded. Hybridoma cell cultures or stably transfected CHO
cells were expanded and supernatant harvested by centrifugation.
Antibody was purified with protein A or G sepharose with acid
elution followed by dialysis in PBS as described previously [27].
Relative Avidity Determination and Competition
Experiments
Anti-human biosensors (ForteBio) were used to capture
HuMabs in PBS (10 mg/ml) followed by binding to various
concentrations of hSOD1 proteins in PBS. Results for association
and dissociation rate constants were calculated and used to derive
the dissociation constant (KD) using the Octet and associated
software (ForteBio). For competitive binding experiments, the first
HuMab in PBS (10 mg/ml) was captured on an anti-human
biosensor followed by binding to hSOD1 protein in PBS
(137 nM). The biosensor was then transferred to the first HuMab
solution to ensure that all antibody binding sites were saturated on
the hSOD1 dimer. Binding was assessed for the second HuMab
after introduction of the biosensor-HuMab-hSOD1 complex into
a solution of the second HuMab in PBS (10 mg/ml).
Generation of apo-hSOD1 and apo-hSOD1-monomer
A hSOD1 variant with the 2 free cysteines mutated (C6A/
C111S) to preclude intramolecular disulfide-bond interchange was
expressed in bacteria without fusion proteins or other tags from the
pET3d vector in BL21-Gold (DE3) Escherichia coli and purified as
previously described [31]. Apo-hSOD1 was generated by
demetallation as described previously [32]. The apo-hSOD1
monomer was generated by introducing 2 additional mutations at
the subunit interface (C6A/C111S/F50E/G51E) and was purified
and demetallated.
Transient Transfection of Human SOD1 WT and Point
Mutants in Human Cells Followed by
Immunoprecipitation
Mammalian expression vector (pcDNA, Invitrogen) encoding
hSOD1 wild type (WT) and engineered mutants (A4V, G85R, and
G93A) with a C-terminal myc tag were previously described [33].
HEK-293T/17 cells were transfected with expression vectors
using lipofectamine 2000 (Invitrogen) as described by the
manufacturer. Cells were harvested with PBS +5 mM EDTA on
day 2 after transfection and lysed with PBS +0.1% Triton X-100
and complete protease inhibitors (Roche). The insoluble material
was removed by centrifugation for 10 min at 14,000 rcf. Soluble
material was immunoprecipitated with 2 mg of antibody and 50 ml
of protein A sepharose beads. Samples were subjected to SDS-
PAGE and immunoblotting with myc tag antibody (9E10) as a
detection agent followed by anti-mouse horseradish peroxidase
conjugate. Immunoblots were developed with chemiluminescent
detection.
Measurement of Increased Hydrophobicity Following
Heating and EDTA Treatment of SOD1
To introduce a convenient protease cleavage site for fusion
protein removal, the sequence encoding hSOD1 containing G85R
or G93A point mutants was removed from pGEX-4T-3 with
BamHI and SalI and ligated to pGEX-6P-1 (GE Healthcare) cut
with the same enzymes. GST-hSOD1-G85R and GST-hSOD1-
G93A were expressed and purified with glutathione beads as
described above for GST-hSOD1-WT. The proteins were cleaved
with PreScission protease (GE Healthcare) according to the
manufacturer protocol. GST, PreScission protease and uncleaved
GST-hSOD1 were removed with glutathione beads. The resulting
hSOD1-G85R and hSOD1-G93A proteins each contained an
additional six amino acids at the N-terminus (GPLGSM) after
protease cleavage and had a native C-terminus. For the
hydrophobicity assay, equimolar amounts of hSOD1 mutant
protein and HuMab, along with 5 mM EDTA (final concentra-
tion) were co-incubated at room temperature or at 45uC for 4
hours (this corresponded to 40 mg of hSOD1 with 200 mg of
HuMab in a final volume of 30 ml). Samples were then cooled to
room temperature and placed in an opaque, black 96-well plate.
To each well, 8-anilino-1-naphthalenesulfonic acid ammonium
salt (ANS, Fisher Scientific) was added to a final concentration of
20 mM and incubated at room temperature for 30 minutes. The
fluorescence was measured on a Victor 3 plate reader (Perkin
Elmer) with an excitation wavelength of 390 nm and emission of
460 nm.
Mutant hSOD1 Mouse Model
Transgenic mice for hSOD1-G93A (B6SJL-Tg(SOD1G93A)1-
Gur/J strain) were obtained from Jackson Laboratories. These
studies were performed in accordance with the recommendations
in the Guide for the Care and Use of Laboratory Animals of the
Human Monoclonal Antibodies to Human SOD1
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National Institutes of Health. The mouse experiments were
performed with approval from the Institutional Animal Care
and Use Committee at University of Massachusetts Medical
School under protocols A-1690 and A-2250. Only male mice were
used to reduce gender differences in disease onset and progression.
For intrathecal (IT) dosing, HuMabs was delivered over 50 days
starting at day 65 from an Alzet 2006 osmotic pump (DURECT
corp.) with an attached catheter implanted into the mouse lumbar
subarachnoid space between the L5 and L6 vertebra as previously
described [34]. Mice had to reach or exceed a weight of 20 g prior
to pump implantation so day 65 was chosen because of mouse size
and allowing approximately 20 to 35 days of HuMab dosing prior
to symptom onset. We chose to use the longest duration pump
available for mice. The pump was primed with each HuMab
(240 ml of 10 to 16 mg/ml for a total 2.4 to 3.8 mg) 24 to 48 hr
prior to implantation and delivered 0.2 ml/hr for 50 days. After 50
days at day 115 when the pump had completed the programmed
delivery duration, the pump and catheter were removed with a
second survival surgery. Any remaining HuMab was collected
from the pump after removal to determine HuMab concentration
and activity. The end stage of disease was defined as the day of
complete paralysis of two limbs as judged by a researcher blinded
to the treatment groups. At disease endpoint, mice were
anesthetized and sera and spinal cord tissue collected. Mice were
perfused with PBS prior to spinal cord tissue removal. Mice were
weighed 2–3 times per week throughout the course of the
experiment. For intraperitoneal (IP) dosing, each HuMab was
given via IP injection starting at day 65 (0.2 ml of 6.25 mg/ml in
PBS, 50 mg/kg final dose) for 3 consecutive days at initial dosing
and then once every 7 days until disease endpoint was reached.
Mice were observed for disease endpoint and spinal cord tissue
collected from a subset of the mice without perfusion. Tissue was
washed briefly in PBS prior to freezing. Survival analysis was
performed using JMP software (SAS) with Mantel-Cox (Log-Rank)
test for probability.
Results
Antibody Generation and Selection for Further
Characterization
To generate a panel of human monoclonal antibodies
(HuMabs) directed against the human SOD1 (hSOD1) protein,
we immunized mice transgenic for human immunoglobulin heavy
and light chain genes [29] (provided by Medarex Inc., a wholly
owned subsidiary of Bristol-Myers Squibb) with various hSOD1
antigens. Spleens from a total of seventeen mice were fused, and
screening with an antigen-specific human IgG ELISA yielded 879
hybridomas reactive to bacterially-produced thioredoxin-hSOD1
fusion protein (Trx-hSOD1-WT-his). To select a unique panel of
HuMabs, we determined and compared the sequences of the
antibody heavy chains, the affinities for Trx-hSOD1-WT-his, and
the antibody epitopes (described in detail in subsequent sections).
Eleven HuMabs were chosen for complete characterization by
selecting a representative antibody from each unique heavy chain
sequence that had an avidity for Trx-hSOD1-WT-his that was
20 nM or lower. An additional selection criterion for the
antibodies was the capacity to bind both hSOD1 with a G93A
mutation (present in our chosen mouse model) and hSOD1 with
an A4V mutation (the most prevalent human mutation in the
North America) [6]. The eleven HuMabs were derived from eight
different mice immunized with a variety of different hSOD1
proteins (Table S1 in File S1). The antibodies represented various
VH and Vk families and contained unique complementarity
determining regions (Tables S2 and S3 in File S1).
To produce the quantities of antibody required for our studies,
the heavy and light chain genes of the selected HuMabs were
cloned into mammalian expression vectors and expressed in CHO
cells. Of note, the HuMab 37 constant region was IgG3 from the
hybridoma but was converted to an IgG1 constant region when
cloned into a mammalian expression vector. Relative avidity for
hSOD1 of cloned HuMab 37 in the context of an IgG1 heavy
chain was essentially identical to that of the IgG3 HuMab 37
produced from the isolated hybridoma (data not shown). Identical
epitope mapping results were obtained with both isotype versions
of the antibody as well (data not shown).
Identification of Linear and Conformation-dependent
Epitopes on hSOD1
To map the amino acids of hSOD1 bound by each HuMab, we
cloned, expressed and purified protein fragments of hSOD1 and
screened for antibody recognition. hSOD1 was divided into four
roughly equal sections which were generated in bacteria as a
fusion protein to thioredoxin (Trx) to increase solubility and
expression levels. The fusion proteins also had a C-terminal 6-
histidine tag to aid in purification. Progressive truncations of the
protein were also made from each terminus, and the central
portion of the protein was expressed to provide overlap if an
epitope fell across the arbitrary divisions between the four major
truncations (Figure 1A). The truncated proteins and full-length
bacterial Trx-hSOD1-WT-his were used in an ELISA-based
screen with HuMabs as detection agents. A 6-histidine tag
antibody was used as a control to ensure that all bacterial proteins
were available for antibody recognition (data not shown). Six of
the hSOD1-specific HuMabs (19, 22, 41, 56, 120, and 155) gave
no detectable signal above background with the truncations and
only recognized the full-length protein (summarized in Figure 1A).
The binding of these six HuMabs was designated as conformation-
dependent since truncation at different ends of the protein caused
a loss of binding suggesting that the overall native conformation of
the protein was lost. To distinguish these HuMabs throughout the
rest of this manuscript, they will be noted with a subscript of ‘c’ for
conformation-dependent (e.g., 41c). The other five HuMabs were
each found to bind a linear sequence of amino acids. HuMabs 3,
16, and 37 recognized amino acids 39–77 as a minimal binding
domain (Figure 1A). HuMab 11 bound to amino acids 77–116,
and HuMab 33 recognized amino acids 102-153 (Figure 1A). To
further define the epitopes and determine if HuMabs 3, 16, and 37
bound distinct regions of the hSOD1 protein, a panel of
overlapping peptides was screened for binding in an ELISA.
Each of the HuMabs recognized a distinct set of peptides with an
epitope of ten amino acids or less and thus each was designated as
binding a linear epitope (data not shown). Two of the HuMabs, 3
and 16, had overlapping epitopes consisting of amino acids 42–49
and 40–47, respectively (summarized in Figure 1B). HuMab 37
had a distinct epitope of amino acids 63–71. The epitope identified
for HuMab 11 was amino acids 80–88 and for HuMab 33 was
amino acids 112–121. To distinguish the HuMabs that bind linear
epitopes throughout the rest of the manuscript, each HuMab
number will have a subscript with an ‘L’ for linear, followed by the
initial amino acid number of the determined minimal epitope (e.g.,
16L-40).
Competition of HuMabs for hSOD1 Binding
To determine if the HuMabs designated as conformation-
dependent bound to distinct or competing epitopes on the hSOD1
protein, an assay was developed to assess simultaneous binding of
two antibodies to the Trx-hSOD1-WT-his protein. This assay
designated the epitopes as distinct if both antibodies could bind the
Human Monoclonal Antibodies to Human SOD1
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protein simultaneously or designated the epitopes as competing if
the binding of the first antibody to hSOD1 prevented the binding
of the second antibody. Each combination of the six conformation-
dependent HuMabs was assayed including swapping the order of
antibody binding. An isotype-matched irrelevant antibody was
included, as well as, controls that lacked antibody or hSOD1
protein. No binding to Trx-hSOD1-WT-his was demonstrated
with either the irrelevant antibody or the no antibody controls
(data not shown). If Trx-hSOD1-WT-his was not included in the
assay, the second antibody was unable to bind indicating that
additional antibody binding was mediated through hSOD1 (data
not shown). The results for the competition analysis are
summarized in Figure 2A with the HuMab bound to Trx-
hSOD1-WT-his first listed to the left of the chart and the HuMab
antibody which was assessed as the second antibody listed across
the top of the chart. Failure of the second antibody to bind is
designated as competing epitopes in dark gray. Simultaneous
binding of the two antibodies is designated as distinct epitopes in
white. Each HuMab competed for binding with itself ensuring that
the binding was saturating for each antibody used (Figure 2A). The
results are summarized in a graphic epitope map with overlapping
circles representing competing epitopes and circles that do not
touch representing HuMabs that can simultaneously bind to the
Trx-hSOD1-WT-his protein (Figure 2B). The epitope for
HuMabs 41c and 120c are similar and may be identical while
the other conformation-dependent HuMabs have unique compe-
tition profiles. The binding of 155c did not prevent the binding of
other conformation-dependent HuMabs suggesting that the
epitope is distinct from the other epitopes. This competition panel
was repeated using commercially-available, natively-expressed
mammalian hSOD1 purified from human erythrocytes (E-
hSOD1) rather than the Trx fusion protein expressed in bacteria.
Identical results were obtained suggesting that the conformation-
dependent HuMabs bind to the E-hSOD1 and Trx-hSOD1-WT-
his proteins in a similar manner (data not shown).
Figure 1. HuMabs recognize different regions of the hSOD1
protein. (A) Full-length hSOD1 (amino acids 1–153) and various
portions of the protein were expressed in bacteria fused to the carboxy-
terminus (C-terminus) of thioredoxin (Trx) and containing a C-terminal
6-histidine tag used for purification (Trx-hSOD1-WT-his). Each protein is
represented in the figure as a hashed line with the beginning and
ending amino acid number listed below the line. The proteins were
coated on ELISA plates and binding of HuMabs (listed at the top right)
detected with goat-anti-human antibody conjugated to alkaline
phosphatase followed by PNPP substrate addition. ELISA results are
listed to the right of the schematic; positive recognition is indicated by
a plus sign while signals equivalent to background are indicated by a
minus sign. HuMabs recognizing only full-length hSOD1 were
designated conformation dependent and are noted below with a C.
HuMabs with an epitope that mapped to a linear sequence of amino
acids are noted below with an L. (B) Minimal linear epitopes were
determined with amino-terminal biotin-labeled overlapping peptides
coated on streptavidin ELISA plates. Binding of HuMabs was assessed as
described in A. The epitopes are noted as a grey box for each linear-
epitope HuMab with the amino acids (aa) bound indicated. To
distinguish these epitopes throughout the rest of the manuscript each
linear-epitope HuMab has a subscripted L for linear followed by the
initial amino acid of the epitope.
doi:10.1371/journal.pone.0061210.g001
Figure 2. Competition of various HuMabs for binding to Trx-
hSOD1-WT-his. (A) HuMabs designated as conformation-dependent
where assayed for simultaneous binding of hSOD1. The HuMab listed to
the left of the graph was bound to an anti-human biosensor and then
allowed to bind Trx-hSOD1-WT-his. The second antibody (listed at the
top of the graph) was then assayed for binding to the biosensor
through interaction with Trx-hSOD1-WT-his. Simultaneous binding of
both antibodies is indicated as a white box. Competing antibodies are
indicated as a dark grey box. (B) The epitopes of the conformation-
dependent HuMabs are represented graphically by overlapping circles.
Circles that do not overlap represent antibodies that can bind the
protein simultaneously. Circles that overlap are competing epitopes.
Based on this profile, the conformation-dependent epitopes were
grouped into five different binding profiles numbered from one to five.
doi:10.1371/journal.pone.0061210.g002
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The competition assay was repeated including HuMabs with
both linear and conformation-dependent epitopes binding to Trx-
hSOD1-WT-his. The linear-epitope HuMabs gave the expected
competition profile with each other based on the mapped epitopes.
HuMabs 16L-40 and 3L-42 competed for binding to Trx-hSOD1-
WT-his while the other HuMabs linear epitopes were distinct and
able to bind the protein simultaneously. The exception was the
inability of HuMab 3L-42 to bind if 37L-63 or 11L-80 were pre-
bound (data not shown). Interestingly, each of the five linear-
epitope HuMabs competed for binding to Trx-hSOD1-WT-his
with each of the six conformation-dependent HuMabs (data not
shown). This was the case whether the linear-epitope HuMab was
bound first or second. It is possible that each of the five different
conformation-dependent epitopes physically overlap with each of
the four linear epitopes. However, given that both conformation-
dependent and linear-epitope HuMabs fall into multiple non-
competing groups, a more likely possibility is that linear and
conformation-dependent HuMabs bind different conformations of
hSOD1 and lock the protein into that conformation preventing
the other type of antibody from binding.
As done with the conformation-dependent HuMabs, the linear-
epitope HuMab competition panel was repeated with the
mammalian-expressed E-hSOD1. We found no detectable binding
for the linear-epitope HuMabs to E-hSOD1 (see next section for
further detail). The conformation-dependent HuMabs were still
able to bind to E-hSOD1 with the same competition profile seen
in Figure 2A. These results suggest that the conformation of E-
hSOD1 is different than that of Trx-hSOD1-WT-his and does not
allow binding of the linear-epitope HuMabs.
HuMab Avidity for Various Forms of hSOD1
To further explore the binding differences found for the linear-
epitope HuMabs, we determined avidity measurements of the
HuMab panel for various forms of the hSOD1 protein. The
hSOD1-specific HuMabs were originally selected to bind Trx-
hSOD1-WT-his generated from bacterial expression and purifi-
cation without additional copper or zinc. Analysis of this protein
with inductively coupled mass spectrometry gave 1.54 zinc
molecules and 0.09 copper molecules per dimer of Trx-hSOD1-
WT-his. Simultaneous analysis of E-hSOD1 gave 0.82 zinc
molecules and 0.83 copper molecules per dimer. The differing
metal content of the two proteins or the presence of a fusion
protein could alter the conformation of the SOD1 protein. Thus,
we used avidity determination to make relative comparisons of the
binding of the HuMabs to Trx-hSOD1-WT-his and E-hSOD1.
Antibody was captured on an anti-human IgG biosensor
(ForteBio) and the association and disassociation rates were
determined using the Octet and associated software. The
calculated affinity constant (KD) for each HuMab is reported in
Table 1. Each HuMab had a high avidity for the Trx-hSOD1-
WT-his protein with KD from 1 to 7 nM. The KD of the
conformation-dependent HuMabs for the E-hSOD1 protein were
similar to constants calculated for Trx-hSOD1-WT-his (Table 1).
In contrast, KD could not be calculated for the linear-epitope
HuMabs for E-hSOD1 as no binding was detected between these
five HuMabs and this mammalian-produced hSOD1 (Table 1).
Similar results were obtained when binding was assessed with a
capture ELISA coating HuMabs on the plate and detecting bound
hSOD1 with a polyclonal antibody (data not shown).
To further understand the HuMab interactions with hSOD1,
two additional forms of hSOD1 were tested that lacked a fusion
protein and had zinc and copper removed. A variant of hSOD1
with the two free cysteines altered to preclude intramolecular
disulfide interchange (C6A/C111S) was produced in bacteria
without fusion proteins or epitope tags [31] and was demetallated
to remove any associated metals (apo-hSOD1) [32]. A monomeric
version was generated by engineering two point mutations (F50E/
G51E) within the dimer interface of the variant with the two free
cysteines removed which was also demetallated to remove any
associated metals (apo-hSOD1-monomer). Avidity was deter-
mined for each HuMab for apo-hSOD1 and apo-hSOD1-
monomer. None of the five HuMabs recognizing linear epitopes
demonstrated significant binding to apo-hSOD1 or apo-hSOD1-
monomer (Table 1). This suggested that removal of the metal or
generation of monomer did not allow binding of linear-epitope
HuMabs. There were two distinct patterns seen with conforma-
tion-dependent HuMabs. Three HuMabs, 22c, 56c, and 155c,
bound apo-hSOD1 with similar avidity as E-hSOD1, but they
failed to bind apo-hSOD1-monomer (Table 1) suggesting that
these HuMabs may require an intact SOD1 dimer for binding. In
contrast, HuMabs, 19c, 41c, and 120c bound the apo-hSOD1-
monomer with KD similar to apo-hSOD1, E-hSOD1, and Trx-
hSOD1-WT-his (Table 1). Similar results were obtained when
binding was assessed with a capture ELISA (data not shown).
When no binding or low binding (6.9 mM for 37L-63 and apo-
hSOD1) was detected with the Octet biosensor, no binding was
detected in the ELISA. Antibody and protein combinations with
KD from 0.2 to 9 nM as measured on the Octet demonstrated
strong signals in ELISA (data not shown).
Binding to WT and Mutant hSOD1 Produced in
Mammalian Cells
To assess HuMab recognition of WT and mutant proteins
produced in a mammalian system, we used transient transfection
of human 293T cells to produce WT and mutant (A4V, G85R and
G93A) hSOD1 tagged with a C-terminal myc tag. Lysate was
generated from transfected cells and HuMab binding assessed
using immunoprecipitation, followed by immunoblot detecting the
myc tag. The backbone plasmid (pcDNA) was transfected as a
negative control, and each of the lysates was incubated with an
irrelevant HuMab followed by immunoprecipitation as an
additional negative control. When lysate was directly subjected
to immunoblot and probed with an anti-myc antibody, a band was
detected at the appropriate size for hSOD1 from the transfected
WT, A4V, G85R, and G93A plasmids, but not for the negative-
control plasmid (Figure 3A) confirming that each protein was
expressed at similar levels. No myc tagged hSOD1 protein was
detected when the lysates were immunoprecipitated with an
irrelevant antibody (Figure 3B). The conformation-dependent
HuMab, 120c, immunoprecipitated all hSOD1-myc proteins
tested (Figure 3C). All conformation-dependent HuMabs with
the exception of 56c were able to bind all hSOD1-myc proteins
tested (summarized in Figure 3E). hSOD1-G85R-myc was not
immunoprecipitated by 56c, and the lack of 56c recognition of the
G85R mutant hSOD1 was confirmed by ELISA with GST-
hSOD1-G85R (data not shown). The linear HuMab, 11L-80, did
not immunoprecipitate the hSOD1-myc or the hSOD1-G85R-
myc but did immunoprecipitate hSOD1-A4V-myc and hSOD1-
G93A-myc (Figure 3D). The lack of 11L-80 recognition of WT
hSOD1 agreed with the lack of 11L-80 binding to E-hSOD1
(Table 1). GST-hSOD1-G85R was used in an ELISA assay to
confirm the lack of 11L-80 binding (data not shown). The G85R
mutation falls in the center of the identified epitope for 11L-80,
amino acids 80 to 88. Because HuMab 11L-80 recognizes a linear
epitope, it is able to recognize any fragments of the hSOD1
protein generated during the cell lysis procedure which are found
as lower bands in the immunoblot. The other linear HuMabs
bound all the mutant hSOD1-myc proteins but not the WT
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(summarized in Figure 3E) in agreement with the lack of binding
to E-hSOD1 (Table 1). The binding of the linear-epitope HuMabs
to hSOD1 point mutants expressed in the mammalian cells
suggests that mutant hSOD1 adopts a conformation similar to the
Trx-hSOD1-WT-his protein which is different than that of WT
hSOD1 produced in mammalian cells. A possible explanation is
that some proportion of both hSOD1 mutants expressed in
mammalian cells and Trx-hSOD1-WT-his expressed in E. coli is
misfolded or unfolded. Previous data has determined that both
A4V and G93A hSOD1 are substantially destabilized with G93A
fully unfolded at 37uC [35]. Our linear-epitope HuMabs did not
bind hSOD1-WT-myc expressed in our mammalian cell system
suggesting that there was not enough misfolded or unfolded
protein for detection in our transient expression system. This
contrasts with previous publications documenting misfolding of
WT hSOD1 protein with transient expression [36] suggesting that
differences in level of hSOD1 expression or different epitope tags
or fusion proteins could affect amounts of WT misfolded protein.
hSOD1 Hydrophobic Exposure and HuMab Inhibition
Mutations in hSOD1 induce a propensity to misfold under
certain conditions and lower the thermodynamic barrier to
misfolding or unfolding [35], [37]. It is possible that antibody
binding could stabilize hSOD1 and reduce the propensity toward
misfolding, unfolding, and aggregation. Or, antibody binding
could stabilize misfolded or unfolded hSOD1 and increase
aggregation. To assess misfolding, unfolding and aggregation, we
measured changes in hydrophobicity of mutant hSOD1 with
exposure to increased temperature and EDTA using the dye ANS
which yields increased fluorescence with increased hydrophobicity.
Protease cleavage was used to remove the GST tag from GST-
hSOD1-G85R and GST-hSOD1-G93A. Protease, uncleaved
GST fusion protein, and GST tag were removed with glutathione
beads to yield purified hSOD1-G85R and hSOD1-G93A. Mutant
hSOD1 proteins, hSOD1-specific HuMabs, and an irrelevant
isotype-matched antibody were separately incubated with 5 mM
EDTA at room temperature or at 45uC for 4 hrs. The proteins
were cooled to room temperature, mixed with ANS, and analyzed
with a fluorescent plate reader. hSOD1-G85R and hSOD1-G93A
both produced a fluorescent signal increase of approximately 7-
fold and 4-fold (respectively) when heated at 45uC as compared to
room temperature (Figure 4A). In contrast, the HuMabs tested
displayed no significant change in fluorescent signal from room
temperature to 45uC (Figure 4A and data not shown). To assay the
effect of HuMabs on the hydrophobic exposure of mutant
hSOD1, we mixed hSOD1-G85R with various HuMabs in the
presence of 5 mM EDTA and incubated for 4 hrs at room
temperature or 45uC followed by analysis of hydrophobicity with
ANS. Irrelevant antibody mixed with hSOD1-G85R had an 8-fold
increase in fluorescence upon heating (Figure 4B) similar to that
seen with hSOD1-G85R alone (Figure 4A). A similar large
increase in fluorescence was obtained when hSOD1-G85R was
separately mixed with HuMabs 155c, 37L-63, or 33L-112 and heated
to 45uC. In contrast, HuMabs 19c, 41c, and 120c separately mixed
with hSOD1-G85R gave no increase in fluorescence when heated
to 45uC for 4 hr (Figure 4B). An intermediate result was obtained
with 16L-40 and 3L-42 mixed with hSOD1-G85R: fluorescence
increased when heated, but only 2.5-fold rather than 8-fold
(Figure 4B). The fluorescence increase of 22c and 11L-80 also gave
an intermediate result, but with a lower statistical difference from
irrelevant antibody (P,0.05) (Figure 4B). Although the magnitude
of fluorescent change from RT to 45uC was not as great with
hSOD1-G93A as it was with hSOD1-G85R (3.5-fold versus 8-
fold), a similar pattern was seen for all HuMabs when mixed with
hSOD1-G93A and heated to 45uC (Figure 4C). Irrelevant
antibody, 155c, 37L-63, and 33L-112 all had a 3-fold or greater
increase in fluorescence with heating to 45uC while HuMabs 19c,
41c, and 120c gave no increase. The intermediate increases of 16L-
40, 3L-42, 22c and 11L-80 separately mixed with hSOD1-G93A had
a lower statistical difference from irrelevant antibody (P,0.10)
(Figure 4C). When mutant hSOD1 was heated prior to addition of
HuMabs 19c, 41c, and 120c, there was a significant fluorescence
increase similar to the irrelevant antibody with mutant hSOD1
(data not shown). This suggests that antibody binding is required
prior to exposure of SOD1 to denaturing conditions to prevent
hydrophobic exposure. In summary, the three conformation-
Table 1. HuMab avidity for various forms of hSOD1.
KD (nM)
Antibodya Epitopeb Trx-hSOD1-WT-his E-hSOD1 apo-hSOD1
apo-hSOD1-
monomer
19c conf #2 1.3 0.2 1.7 6.1
41c conf #1 5.6 6.5 5.4 3.0
120c conf #1 2.0 1.0 2.6 8.9
22c conf #4 4.1 1.1 5.0 none
56c conf #3 5.2 6.8 4.1 none
155c conf #5 7.3 2.2 1.6 none
16L-40 aa 40–47 5.6 none none none
3L-42 aa 42–49 6.7 none none none
37L-63 aa 63–71 2.1 none 6940 none
11L-80 aa 80–88 5.5 none none None
33L-112 aa 112–121 5.0 none none None
aFor clarity in the manuscript, antibody number has a subscript to denote epitope: conformation-dependent epitope (C) and linear epitope (L and the first amino acid
number of the epitope).
bepitope was narrowed to ten amino acids (aa) or less for linear epitopes with the aa numbers listed and conformation-dependent epitopes (conf) were categorized
with competitive binding assays into different categories numbered 1 through 5 (see Figure 2).
doi:10.1371/journal.pone.0061210.t001
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dependent HuMabs that could bind apo-hSOD1-monomer
(Table 1) were able to prevent hydrophobic exposure upon
heating possibly through stabilization of monomer. The two
linear-epitope HuMabs with overlapping epitopes, 16L-40 and 3L-42,
reduced hydrophobic exposure which could be reduction in
aggregation due to the binding of hSOD1 beta-sheet four. The
linear-epitope HuMab 11L-80 and conformation-dependent Hu-
Mab 22c may provide a reduction in hydrophobic exposure
although the results were less significant.
Antibody Delivery to hSOD1-G93A Transgenic Mice
A commonly used transgenic hSOD1 mouse model with a high-
copy number of hSOD1-G93A (B6SJL-Tg(SOD1G93A)1Gur/J
strain) [17] was used to determine the therapeutic potential of anti-
hSOD1 HuMabs. A small exploratory experiment with two to five
mice per HuMab was performed to assess potential adverse effects
of HuMab delivery into mouse cerebrospinal fluid. The hSOD1-
specific HuMabs and an irrelevant HuMab (ten mice) were
delivered intrathecally by surgical implantation of an osmotic
pump with a lumbar intrathecal (IT) catheter as performed
previously for RNAi delivery in this model system [34]. Antibody
delivery was initiated at day 65 (mouse age) prior to onset of
symptoms and continued until day 115 when the pump
mechanism was exhausted and it was removed. Animals were
observed daily for the endpoint criteria of complete two limb
paralysis. Antibody delivery for 50 days was completed for all
tested HuMabs with no obvious toxicity (data not shown). The
animal group size in this experiment was too small to yield
statistical significance in delay of disease endpoint versus an
irrelevant antibody (Table S4 in File S1). Therefore, two HuMabs
with the longest delay in disease endpoint in the pilot experiment
were further tested with larger animal groups. HuMab 120c,
HuMab 37L-63, and an irrelevant antibody were each delivered IT
to 19 to 23 mice per antibody. The duration to disease endpoint
from birth was 131 days for irrelevant antibody and 131 and 133
days for HuMabs 120c and 37L-63 respectively (Figure 5A). The
change from irrelevant antibody was not statistically significant for
either HuMab120c or 37L-63. For the small pilot experiment
(Table S4 in File S1), the average duration to disease endpoint
from birth was 133 days for both HuMabs 120c and 37L-63. The
results are similar to those obtained with the pilot experiment,
however, the average duration to disease endpoint for the
irrelevant antibody was 122 days for the pilot experiment (n
= 10, Table S4 in File S1) versus 131 days for the larger
experiment (n = 22, Figure 5B). This difference could be due to
sampling error with a smaller group or because care was not taken
to distribute siblings amongst different groups in the pilot
experiment which was corrected in the larger group experiment.
Residual antibody remaining in the osmotic pump at time of
removal from the 50 day dosing in a mouse was tested in ELISA
for binding to hSOD1 and the activity was found to be equivalent
to antibody stored at 4uC for the same duration of time (Table S5
in File S1).
An alternate delivery method of weekly intraperitoneal (IP)
injection was also tested. IP injection of 50 mg/kg of HuMab 37L-
63 and an irrelevant antibody was initiated at day 65 and
continued weekly throughout the experiment to groups of 16 or 15
hSOD1-G93A mice respectively. The mean duration to disease
endpoint was 129 days for irrelevant antibody and 133 days for
HuMab 37L-63 (Figure 5B). The four-day extension of mean
disease endpoint for the HuMab 37L-63 treated group did not
reach statistical significance.
To assess HuMab distribution and concentration in these two
experimental models, we retrospectively analyzed available sera
and spinal cord tissue that had been collected from mice at the
time of disease endpoint. A quantitative anti-human antibody
ELISA was performed to measure levels of HuMabs in the serum
and tissue. Spinal cord lysate was analyzed for all mice that
received IT delivery and was expressed as ng of HuMab per mg of
total protein in the lysate. For the majority of the mice (tissue
sample harvested from 2 to 34 days post-pump removal), the
Figure 3. HuMab immunoprecipitation of WT and mutant
hSOD1 from mammalian cells. A human derived cell line (293T) was
transiently transfected with vectors engineered to express myc-tagged
wild type (WT) or mutant hSOD1 (A4V, G85R, or G93A), or with empty
vector as a control (neg). (A) Lysate from transfected cells was subjected
to SDS-PAGE and immunoblot. Myc tagged proteins were detected
with a mouse monoclonal antibody specific for the myc tag followed by
goat anti-mouse HRP conjugate and chemiluminescence. An arrow to
the right of the blots indicates a band present at the expected size for
SOD1 (16 kDa). Lysate from transfected cells was mixed with an
irrelevant isotype-matched antibody (B), HuMab 120c (C), and HuMab
11L-80 (D) and incubated at ambient temperature for 2 hrs followed by
immunoprecipitation (IP) with protein A sepharose beads. Precipitated
material was subjected to SDS-PAGE and immunoblotted with the anti-
myc antibody. (E) Additional immunoprecipitations where performed
with the remaining HuMabs, and the presence or absence of a band at
the appropriate size for SOD1 in anti-myc immunoblots is indicated
with a plus or minus.
doi:10.1371/journal.pone.0061210.g003
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concentration of HuMab was below the limit of detection
(,1.5 ng/mg) (Table S6 in File S1). Only two mice had levels of
HuMab .1.5 ng/mg after pump removal with 46.6 ng/mg
present one day after pump removal and 1.8 ng/mg present at
6 days after pump removal. Three of the mice had tissue samples
harvested prior to pump removal, and all three had detectable
levels of HuMab from 1.4 to 11.8 ng/mg. HuMab level in serum
was tested for six mice. Two mice were tested at 20 days after
pump removal (end of antibody dosing) and had 0.3 mg/ml and
81 mg/ml of HuMab detectable in serum (Table S6 in File S1).
The other four assayed mice ranged from 23 to 34 days after
pump removal and had HuMab concentration in the sera below
the limit of detection (,0.15 mg/ml). It is possible that the mouse
with 81 mg/ml of HuMab in the serum at 20 days after pump
removal had a misplaced catheter that delivered the HuMab
systemically.
For IP delivery, spinal cord lysate had 41 and 20 ng of HuMab
per mg of total protein for two mice treated with irrelevant
antibody and 2 and 5 ng/mg for two mice treated with HuMab
37L-63 (Table S7 in File S1). For IP delivery, HuMab serum level
was analyzed in three mice and ranged from 200 to 800 mg/ml.
We limited the sera collection during the experiment because of
concerns that it would affect the disease course so a separate
experiment was done to verify consistent levels of antibody in sera
from IP dosing. Isotype-matched irrelevant HuMab was dosed IP
at 50 mg/kg once a week in normal mice over a course of 10
weeks, and gave a similar range of a serum HuMab levels
throughout the entire time of dosing (Table S8 in File S1). These
mice did develop anti-human antibodies after the fourth week of
injections, but this did not lower the average HuMab serum
concentrations at day 7 after injection through the length of the
experiment.
To provide a more direct comparison of delivery methods to
different regions of the spinal cord and brain, irrelevant human
antibody was delivered to normal mice IT (n = 5) and IP (n = 3)
for two weeks and human antibody level was quantified from sera
and different regions of the spinal cord and brain. Mice were
perfused with PBS prior to the tissue harvest for both delivery
methods. With IP injection, high levels of human antibody were
detected in the sera (544647 ug/ml, average of three mice) and
antibody was evenly distributed in the lumbar and cervical spinal
cord and four different regions of brain tissue at 26 to 39 ng/mg
total protein (Table S9 in File S1). With IT pump delivery,
antibody was present primarily in lumbar spinal cord (1365 ng/
mg, average of five mice) with a lower level in cervical spinal cord
(262 ng/mg) and below the limit of detection in the four different
sections of brain (,1.5 ng/mg). Antibody was present at an
average of 5164 mg/ml in the sera of the five IT-treated mice.
From these measurements, we conclude that the IP delivery
method gave higher levels of antibody in the nervous tissue and
could be delivered for a longer period of time in the disease model
with fewer complications from surgery. However, we were not able
to completely rule out that the levels of antibody detected in the
spinal and brain tissue is an artifact from the high levels in the
blood with subsequent contamination of the tissues during
dissection and removal.
Figure 4. Increased hydrophobicity of hSOD1 can be inhibited
by a subset of hSOD1 specific HuMabs. (A) hSOD1-G85R, hSOD1-
G93A, various hSOD1-specific HuMabs, and an irrelevant isotype-
matched antibody (IR Mab) were separately incubated with 5 mM EDTA
at room temperature (RT) or 45uC for 4 hrs. Hydrophobicity was
measured with ANS dye fluorescence using a Victor 3 plate reader at
390 nm excitation and 460 nm emission and is reported as the fold
change in relative fluorescence units from RT to 45uC. hSOD1-G85R (B)
and hSOD1-G93A (C) were mixed with irrelevant antibody or various
HuMabs with 5 mM EDTA and incubated at RT or 45uC for 4 hrs.
Hydrophobicity was measured as indicated above. The mean of
replicates is noted with a thick black bar with the standard deviation
indicated. Samples with insufficient material for replicates are indicated
with the single data point as a thick grey bar. Statistical significant
differences from irrelevant antibody were determined using a Student’s
t-test with P,0.01 (***), ,0.05 (**), and ,0.10 (*) indicated above the
black bar for each sample.
doi:10.1371/journal.pone.0061210.g004
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Discussion
We have selected hSOD1 specific HuMabs with a range of
distinct epitopes. The five HuMabs recognizing linear epitopes
were only able to bind some form of misfolded or unfolded
hSOD1. The lack of binding to properly-folded hSOD1 agrees
with the location of the epitopes in the three-dimensional structure
of hSOD1 (Figure 6) [11]. Four of the epitopes (16L-40, 3L-42, 11L-80,
and 33L-112) are located within the beta-sheets that form the back of
the metal-binding pocket. HuMabs 16L-40 and 3L-42 bind in a region
(amino acids 42–48) that was previously characterized with a
polyclonal antibody (USOD) generated to the peptide. Similar to
what we have found with the monoclonal antibodies, 16L-40 and 3L-
42, USOD was not able to bind properly folded dimer or monomer
hSOD1 but recognized unfolded hSOD1 [38]. USOD specifically
stained inclusions within motor neurons in spinal cord tissue from
two different SOD1 mutant fALS cases but not tissue from five
different sALS cases [38]. We would anticipate that 16L-40 and 3L-42
would have similar binding, but this remains to be tested. The fifth
epitope (37L-63) is present on one side of the zinc-binding loop and
the other side of the same loop has a portion of the 11L-80 epitope.
Very little of these epitopes would be accessible to antibodies as
imaged with a space-filling model of the hSOD1 crystal structures
(Figure 6 B and D). HuMab 37L-80 has the largest amount of the
epitope visible in the space-filling model (Figure 6B), and is the only
linear-epitope HuMab with measurable low avidity to apo-hSOD1
(Table 1). Each of the linear epitopes contains at least one amino
acid involved in zinc or copper chelation. If the zinc-binding loop
and the electrostatic loop that form the front of the metal-binding
pocket were flexible (from loss of bound metals and/or disulfide
bonding), the epitopes may become accessible as the loops move
and allow access to the beta-sheets at the back of the metal-binding
pocket. Previous studies exploring the crystal structure of A4V and
G93A apo-hSOD1 [39] or the solution NMR structure of various
forms of hSOD1 [40] suggest that there is large flexibility in the
zinc-binding and electrostatic loops when metal is not bound.
Interestingly, we found that the linear-epitope HuMabs could not
bind apo-hSOD1. These same linear-epitope HuMabs did bind
Trx-hSOD1-WT-his and GST-hSOD1-WT fusion proteins sug-
gesting that the lack of metal may not provide enough structural
disturbance for the binding of a large antibody molecule and a
second structural change such as a point mutation like A4V or
G93A or attachment of a fusion protein is required for HuMab
binding. Alternatively, the intramolecular disulfide bond may need
to be reduced in combination with lack of metal to produce enough
flexibility for antibody binding. Future structural studies with
hSOD1 bound by linear-epitope HuMabs could provide under-
standing of the exact hSOD1 conformation required for HuMab
binding.
The identified hSOD1 specific HuMabs had two distinct groups
of conformation-dependent epitopes that presumably bind non-
linear epitopes. One group of HuMabs (22c, 56c, and 155c) had an
epitope that was only available on hSOD1 dimer. These
antibodies either bound an epitope that spans the dimer interface,
or that has a conformation-dependent epitope only present on the
dimer. The other group of conformation-dependent HuMabs (19c,
41c, and 120c) had an epitope that was available on hSOD1
monomer and dimer. Only the three HuMabs that could bind to
hSOD1 monomer were able to prevent any increase in
hydrophobic exposure from mutant hSOD1 subjected to dena-
turing conditions. The epitope bound by these three HuMabs
could be a key region on hSOD1 for stabilizing the properly-
folded protein and thus preventing unfolding. Or, binding to
monomer could be a key step in preventing hSOD1 misfolding
and aggregation as monomerization is likely an early step in the
misfolding pathway in vitro [41]. A polyclonal antibody specific for
the exposed dimer interface (SEDI) is able to recognize hSOD1 in
inclusion structures within neurons suggesting that monomeric
Figure 5. Antibody delivery to hSOD1-G93A transgenic mice.
(A) HuMabs 37L-63 (red) and 120c (green) and an irrelevant isotype-
matched HuMab (IR Mab, blue) were delivered to the lumbar intrathecal
space of hSOD1-G93A transgenic mice via osmotic pump from mouse
age 65 to 115 (days). Complete two limb paralysis was used as an
endpoint of disease and the day of disease endpoint was used to
calculate the percent survival each day. For each group, the mean days
to reach the endpoint (mean survival) and P value from the Mantel-Cox
test (log-rank) were calculated using JMP and are listed below the
graph. (B) HuMab 37L-63 (red) and an irrelevant isotype-matched HuMab
(IR Mab, blue) were delivered by intraperitoneal injection to hSOD1-
G93A transgenic mice. Antibody dosing was initiated at mouse age of
65 days and continued once per week for the duration of the mouse
survival. Endpoint and statistics were calculated as above.
doi:10.1371/journal.pone.0061210.g005
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hSOD1 is present in ALS patient tissue [42], [43]. It is not clear if
binding and stabilizing monomer would translate directly to a
benefit in vivo as other aspects may be important for disease
treatment. However, a recent report of a 40 day increase in
survival time in G37R hSOD1 transgenic mice with SEDI peptide
immunization is suggestive that monomer recognition may have a
benefit in vivo [25].
The binding of both the linear and conformation-dependent
HuMabs to Trx-hSOD1-WT-his purified from bacteria suggests
that the protein has enough intact structure for the conformation-
dependent HuMab binding and is flexible enough to expose the
linear epitopes at the back of the metal-binding pocket. The
concept that the protein has to change from the native
conformation to allow binding of the linear-epitope HuMabs is
supported by lack of all conformation-dependent HuMab binding
to Trx-hSOD1-WT-his if any of the linear-epitope HuMabs are
pre-bound to hSOD1. This ability to lock the protein in a
conformation that is not recognized by the other group of
HuMabs is reciprocal. This panel of HuMabs should prove useful
to probe the structure of hSOD1 in solution as hSOD1 may only
expose some conformations transiently which could be trapped by
an antibody for further study. Similarly, hSOD1 conformations
could be assessed in complex samples such as patient tissue, sera or
Figure 6. HuMab epitope location in predicted hSOD1 structure. (A) The crystal structure of one monomer of a hSOD1 dimer (2C9V) is
indicated in ribbon model from Rasmol. The bound zinc is indicated as a yellow sphere. The two cysteines involved in the intramolecular disulfide
bond (C57 and C146) are displayed as wireframe in light blue. The phenylalanine at position 50 and glycine at position 51, two residues mutated at
the dimer interface to generate apo-hSOD1-monomer, are displayed as wireframe in dark grey. HuMab epitopes are indicated as follows: 16L-40 amino
acids 40–47 in yellow, 3L-42 amino acids 42–49 in red, the overlap of these two epitopes is orange, 37L-63 amino acids 63–71 in dark blue, 11L-80 amino
acids 80–88 in purple, and 33L-112 amino acids 112–121 in green. (B) The same orientation molecule in (A) is displayed as a space-filling model. (C) The
ribbon model from (A) is rotated 90 degrees on the x-axis to view from the bottom of the molecule in (A). (D) The same orientation molecule in (C) is
displayed as a space-filling model.
doi:10.1371/journal.pone.0061210.g006
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spinal fluid where there may be multiple forms and versions of
hSOD1 protein [44].
Unfortunately, due to the prohibitive high cost of the in vivo
experiments, we were not able to test the entire panel of eleven
HuMabs in an ALS animal model. We selected one linear-epitope
HuMab, 37L-63, and a conformation-dependent HuMab, 120c,
that bound to hSOD1 dimer and monomer. The G93A high-copy
mouse model was used because of the rapid disease onset and
progression with an average survival of ,130 days. This allows for
a shorter period of antibody treatment that fits within the limits of
the osmotic pump delivery time. The rapid onset of symptoms is
likely due to the higher level of mutant hSOD1 expression because
of the higher transgene copy number. This yields a level of mutant
hSOD1 that is approximately 20-fold higher than in human ALS
and thus may pose a greater challenge for treatment [17]. Our
in vivo testing results did not replicate the previous data with
passive immunotherapy of mutant hSOD1 transgenic mice via
osmotic pump, which provided a 5 to 9 day survival benefit [23],
[26]. However, there are many different variables that may
contribute to the lack of benefit in our experiment: route of
administration (IT versus intraventricular), disease endpoint
(complete two limb paralysis versus 30 seconds to right), genetic
background of the mouse (B6SJL versus C57BL/6), species of the
antibody (human versus mouse), and epitope of the antibody. In
our testing we chose IT delivery because this delivery of siRNA
had afforded distribution throughout the mouse central nervous
system (CNS) and demonstrated a statistically significant survival
extension [34]. However, with IT delivery, we found that antibody
was present in the lower spinal cord and was cleared very quickly
from the spinal cord after pump removal. Previous passive
immunotherapy in ALS mouse models delivered antibody into
the left ventricle of the brain [23], [26]. It is possible that this
location of delivery and distribution is required in the G93A
hSOD1 transgenic mouse model to demonstrate an extension in
survival. It is not clear if distribution of the antibody throughout
the spinal cord and brain would be required in treatment of the
human disease as the levels of mutant hSOD1 are much lower
than the G93A hSOD1 transgenic mouse model.
To address some of the issues with the IT antibody delivery and
distribution, we tested an alternative method of delivery by IP
injection, which allowed the antibody to be dosed to the disease
endpoint even when the mice would have been too weak to carry
the additional weight of an osmotic pump. The IP delivery of
HuMab 37L-63, gave an encouraging trend toward extended
survival that was not statistically significant. We found detectable,
evenly distributed HuMab in the mouse CNS suggesting that this
route may provide antibody delivery to the brain without invasive
surgery. HuMab 37L-63 levels in the serum and spinal cord were
five- to ten-fold lower than an irrelevant isotype-matched antibody
(Table S7 in File S1) suggesting that this specific antibody may
have a solubility, transport, or half-life issue that lower the
available antibody for therapeutic efficacy. Given the encouraging
trend seen with HuMab 37L-63, IP delivery of other HuMabs such
as one with the capacity to bind to apo-hSOD1-monomer is an
attractive next step to provide a clearer demonstration of in vivo
efficacy. HuMab IP delivery to ALS mouse models with longer
time for disease onset (G37R, G85R, or low-copy G93A) and
endpoints other than survival extension (reduction in motor
neuron loss, reduction in mutant hSOD1, or muscle strength and
motor assessments) may afford a clearer picture of HuMab
efficacy. This was recently demonstrated with immunization of the
SEDI peptide not providing a significant change in duration of
survival for high-copy G93A hSOD1 transgenic mice while a
statistically significant extension of 40 days of survival was seen
with G37R hSOD1 transgenic mice [25]. Bapineuzumab and
solanezumab are both in human clinical trials and are dosed
systemically to patients for Alzheimer’s disease treatment suggest-
ing that systemic HuMab delivery could be a viable method for
antibody treatment of other CNS disease targets [45].
It has proven extremely difficult to translate treatments from
ALS animal models into humans [20]. A prime example is
Riluzole, the only approved drug for ALS, providing variable
results in the G93A transgenic mouse model with a modest
extension of 14 days for survival [21] to no statistically significant
extension of survival [22]. It may be that the animal models are
not able to recapitulate all of the factors involved in the human
pathology and disease or that there are differences in treating
SOD1 mutant ALS and sALS. This presents a challenge when
selecting compounds to introduce into human clinical trials.
Recent publications detecting higher levels of a subset of SOD1
antibodies in long-term survivor ALS patients [46], misfolded
SOD1 in sALS [7], [9], and SOD1 misfolding when FUS and
TDP43 are mislocalized [47] provide evidence that SOD1 has
potential as a therapeutic target in fALS and sALS.
Supporting Information
File S1 Tables S1, S2, S3, S4, S5, S6, S7, S8, S9.
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